NCT01468038

Brief Summary

This is a double blind placebo controlled study of one hundred and four subjects which will be randomized for treatment with Sentra PM alone, Sentra PM with trazadone, trazadone alone and placebo alone. Twenty -six subjects will be randomly placed in one of the four groups. Each of the one hundred and four subjects will undergo baseline examination to include a sleep study questionnaires and 24- hour electrocardiographic recording. The one hundred and four subjects will then be randomly placed in one of the four groups.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
111

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Apr 2008

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2008

Completed
6 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2008

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

November 5, 2011

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 9, 2011

Completed
Last Updated

November 9, 2011

Status Verified

November 1, 2011

Enrollment Period

6 months

First QC Date

November 5, 2011

Last Update Submit

November 8, 2011

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to fall asleep

    Subjects time to fall asleep will be measure by patient response to questionnaires to determine if time improved, stayed the same or worsen.

    14 days

Secondary Outcomes (5)

  • Quality of Sleep

    14 days

  • Morning grogginess

    14 days

  • Feelings of depression

    14 days

  • Feelings of anxiety

    14 days

  • Improvement in parasympathetic activity

    14 days

Study Arms (4)

Active trazodone and placebo

ACTIVE COMPARATOR

trazodone 50mg with Sentra PM-like placebo

Drug: Trazodone

placebo and active Sentra PM

ACTIVE COMPARATOR

Trazodone-like placebo and Sentra PM

Other: Sentra PM

Sentra PM and trazodone

ACTIVE COMPARATOR

Active Sentra PM and active trazodone

Drug: Sentra PM and Trazodone (CoPack Kit Trazamine)

placebo trazodone and placebo Sentra PM

PLACEBO COMPARATOR

trazadone-like placebo and Sentra PM-like placebo

Drug: Placebo trazodone and placebo Sentra PM

Interventions

active trazodone and sentra pm-like placebo

Active trazodone and placebo

Active Sentra PM and trazodone-like placebo

placebo and active Sentra PM

A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.

Sentra PM and trazodone

Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.

placebo trazodone and placebo Sentra PM

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females over the age of 18 and below age 65.
  • Patients with a history of a sleep disturbance with non-restorative sleep defined by perceived increase in sleep latency or morning/daytime grogginess.

You may not qualify if:

  • Subjects who have previously taken GABAdone, SentraPM or trazadone.
  • Subjects who are currently taking tricyclic anti-depressants.
  • Any blood chemistry anomalies the investigator finds that may put the patient at risk or invalidate study results.
  • Pregnant or lactating females.
  • Subjects with implanted pacemakers or other implanted electrical devices

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Targeted Medical Pharma

Los Angeles, California, 90077, United States

Location

MeSH Terms

Conditions

Sleep Wake Disorders

Interventions

Trazodone

Condition Hierarchy (Ancestors)

Nervous System DiseasesNeurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and SymptomsMental Disorders

Intervention Hierarchy (Ancestors)

PiperazinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPyridonesPyridines

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 5, 2011

First Posted

November 9, 2011

Study Start

April 1, 2008

Primary Completion

October 1, 2008

Study Completion

December 1, 2008

Last Updated

November 9, 2011

Record last verified: 2011-11

Locations